Press releases appear below, filter by date.
Published updates reflect the Second 2012 Edition of the Code.Following recent changes to the ABPI Code of Practice for the Pharmaceutical Industry, the PMCPA has updated its popular e-learning module and quick guides to the Code.
Grünenthal Ltd and Vifor Pharma UK Limited have each breached Clause 2 of the ABPI Code of Practice and are the subject of advertisements in the medical, pharmaceutical and nursing press. In addition, Grünenthal has been publicly reprimanded.
Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry have been sent to companies and published on the PMCPA website.
The 2012 Code will come into effect on 1 January 2012 with a transitional period between 1 January 2012 and 30 April 2012. During this time no promotional material or activity will be regarded as being in breach of the Code if it fails to comply with its provisions only because of newly introduced requirements.
There are different transitional provisions for Clauses 17.2 and 23.8. Details are given in the supplementary information for those clauses.
Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry were agreed by the ABPI on 3 November 2011.
Bayer Healthcare has breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press.
Chiesi Limited, Eli Lilly and Company Limited and Bayer Healthcare have each breached Clause 2 of the ABPI Code of Practice. Bayer Schering Pharma has been publicly reprimanded.
Allergan Limited and Cephalon (UK) Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry. To highlight these breaches, both are the subject of advertisements in the medical, pharmaceutical and nursing press.
Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd and Napp Pharmaceuticals Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry.
